Clinical Trials in Houston

Showing 14361-14380 of 17,885 trials

BATTLE Program: Sorafenib in Patients With NSCLC

NCT00411671

Primary Objective: * To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen. Secondary Objective: The secondary objectives of this study will be to: * Determine the overall response rate * Determine the overall survival * Determine the time to disease progression * Assess the safety/toxicity of the study treatment * Assess biomarker modulation in the tumor tissue and serum samples from the treatment. * Assess plasma and intra-tumor concentrations of study treatment

Lung Cancer

M.D. Anderson Cancer Center105 participantsStarted Nov 2006

Houston, Texas, United States

TERMINATEDPhase 2< 1 mile

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

NCT01200342

The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.

Melanoma

M.D. Anderson Cancer Center7 participantsStarted Dec 2010

Houston, Texas, United States

COMPLETEDPhase 1< 1 mile

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT00533585

The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). The safety and effectiveness of this drug combination will also be studied.

Lung Cancer

M.D. Anderson Cancer Center23 participantsStarted May 2006

Houston, Texas, United States

BATTLE Program: Sorafenib in Patients With NSCLC

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Find Trials by Condition in Houston

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours

Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

AqueSys Microfistula Implant in Refractory Glaucoma

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

TearLab Refractive Surgery Dry Eye Study

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)